Coronavirus | COVID-19 vaccine still possible this year: AstraZeneca

Company ‘voluntarily paused’ trial after unexplained illness in a volunteer

Updated - September 10, 2020 10:52 pm IST

Published - September 10, 2020 10:27 pm IST - London

Under phase-II, trials were conducted at Bharti Vidyapeeth Medical College and also KEM Hospital in the city.

Under phase-II, trials were conducted at Bharti Vidyapeeth Medical College and also KEM Hospital in the city.

Drugs giant AstraZeneca on Thursday said a COVID-19 vaccine could still be available by as early as the end of the year, despite a randomised clinical trial being paused.

“We could still have a vaccine by the end of this year, early next year,” the U.K.-based company’s chief executive Pascal Soriot said in comments at a media event.

AstraZeneca announced on Wednesday it had “voluntarily paused” its trial of a drug developed alongside Oxford University after a U.K. volunteer developed an unexplained illness.

An independent committee was drafted in to review safety but the company said it was a “routine action” designed to maintain the integrity of the trials.

“We will be guided by this committee as to when the trials could restart, so that we can continue our work at the earliest opportunity,” Mr. Soriot said in a statement.

AstraZeneca’s vaccine candidate is one of nine around the world currently in late-stage Phase 3 trials.

In the U.S., the company began enrolling 30,000 volunteers across dozens of sites on August 31, and smaller groups are being tested in Brazil and elsewhere in South America.

The vaccine, called AZD1222, uses a weakened version of a common cold-causing adenovirus engineered to code for the spike protein that the novel coronavirus uses to invade cells.

After vaccination, this protein is produced inside the human body, which primes the immune system to attack the coronavirus if the person is later infected.

The director of U.K. scientific research charity the Wellcome Trust, Jeremy Farrar, said there were often pauses in vaccine trials.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.